Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients
about
sameAs
Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic ImplicationsNew Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal CancerAn update on microRNAs as colorectal cancer biomarkers: where are we and what's next?Rectal cancer stagingEfficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.Neo-adjuvant chemoradiotherapy; an opportunity in sphincter preserving procedure for rectal cancer.Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy.Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery.Rectal cancer treatment: improving the picture.Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors.Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer.Microarray profiling of mononuclear peripheral blood cells identifies novel candidate genes related to chemoradiation response in rectal cancer.Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.Pathologic response of primary rectal cancer to oxaliplatin-based chemotherapy.Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancerMethylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective studyChemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancer.Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials.Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging.Preoperative versus postoperative treatment for locally advanced rectal carcinoma.Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.A novel histologic grading scheme based on poorly differentiated clusters is applicable to treated rectal cancer and is associated with established histopathological prognosticators.Preoperative chemoradiation for locally advanced rectal cancer: comparison of three radiation dose and fractionation schedules.Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patientsPathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcomeDiabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer.Neoadjuvant treatment of rectal cancer: where are we now?Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.Preoperative Chemoradiation in Locally Advanced Rectal Cancer: Efficacy and Safety.Abdominoperineal resection: how is it done and what are the results?Chemoradiotherapy response in recurrent rectal cancer.Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy?Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?Outcomes in the surgical treatment of low rectal cancer: does neoadjuvant treatment equalize results?
P2860
Q26778222-3A3029BF-0F9E-4CD6-ABD5-E9208B8544FFQ26786311-7AE7CD33-26B0-4FC3-B2AE-BD84EC176011Q27024427-8D799489-9AA3-4529-B65B-BCBF87311808Q30484651-6573E145-1CE5-44EE-B2F8-2ECC2A21273AQ33438899-1F0C7CD6-56EC-42F3-AA96-B069127E580EQ33596791-B309F3BC-51AC-47FD-8B6C-82DE12C9CB82Q33637997-F7797E05-7C3F-4772-90DB-AAF25AF46DA4Q33820817-98D7663A-85FF-45A4-AEB8-F04248D4DDE4Q33997798-B751D3AD-24CA-4411-9FB5-8331C33807ACQ34101866-008D5682-2653-4D9D-AEFD-DAEABDBBF177Q34382761-1DBF3938-D0B9-4536-B18E-45D33952957DQ34599442-E583E379-25E8-4316-A4A2-7A0E6D2593F3Q34743494-80D7AECC-6CC1-457F-BD12-FAB8B066CD87Q34932625-48DFD3C7-8AB3-4050-A48A-E80FD1ED5600Q34989668-ED560595-3B5D-469C-BFA0-AE63F96C299BQ35013576-93ADFB56-3A2E-49A8-AD5B-F3BAA0AA5FB0Q35117930-0A9C3CDD-1BB8-47C4-B2AA-7CB67F4646F9Q35460703-13E6D33C-C487-4D41-9FEA-507281AC8943Q35623320-56E90C1F-A30C-44FE-99BA-654F18E51F4FQ35758067-9BD1AEDB-B4AF-4A42-AC58-0A6CE713929EQ36216917-7468DAB1-C04A-4EEA-BE98-734E41BAEFB8Q36263852-FCB8E5D8-9EFE-4958-A404-84E707B15C43Q36343876-49B12848-9384-4A67-A990-A61A08612B58Q36429439-F6DBAECB-0C8A-4FB2-BDBD-7548E62599BCQ36646705-26362348-F94D-4EBD-9792-579FC1F282C2Q36903261-02FBE0FC-2074-48EA-AFDA-970EF44221FBQ37079063-ABD1361A-A0AF-44CC-9790-9F06138326BFQ37119089-190197D6-2218-48A9-9662-4EEA5583F8E4Q37131682-153FEF60-6063-45B8-9245-E01D94854CD9Q37140736-F3F9D2E7-64DA-4DE6-87A4-FA28BC37A28BQ37158143-A4F338AB-A52B-47C4-8F91-9E412C90CDD9Q37238569-EBD94909-69CA-434D-B97E-2DC3F4DF7F2FQ37311450-BD61978A-FCF7-4785-99C4-3551ED4D23F4Q37462249-FE498553-169E-4E93-98BD-9ADDDDB12E8FQ37595254-54766A70-5DE4-4388-A240-9DD53A36426AQ37686375-F032EDA5-22F4-4483-B2A2-0268CC63BEB4Q37955677-EFA152BB-5CCC-4E82-AA34-587859BA521FQ38079162-CC7C1D69-1492-4998-9A98-AAA7C963D302Q38208009-2B29DCFB-0E96-4C34-91E6-AD953FBF1EE9Q38236794-B1AA312A-1041-4299-8AA7-249187290D02
P2860
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Does downstaging predict impro ...... -term analysis of 165 patients
@ast
Does downstaging predict impro ...... -term analysis of 165 patients
@en
Does downstaging predict impro ...... -term analysis of 165 patients
@nl
type
label
Does downstaging predict impro ...... -term analysis of 165 patients
@ast
Does downstaging predict impro ...... -term analysis of 165 patients
@en
Does downstaging predict impro ...... -term analysis of 165 patients
@nl
prefLabel
Does downstaging predict impro ...... -term analysis of 165 patients
@ast
Does downstaging predict impro ...... -term analysis of 165 patients
@en
Does downstaging predict impro ...... -term analysis of 165 patients
@nl
P2093
P3181
P1476
Does downstaging predict impro ...... -term analysis of 165 patients
@en
P2093
Antonella Ciabattoni
Aurelio Picciocchi
Brunella Barbaro
Claudio Coco
Fabrizio Ambesi-Impiombato
Francesco Cellini
Gennaro Nuzzo
Gian Battista Doglietto
Lucio Trodella
Maurizio Cosimelli
P304
P3181
P356
10.1016/S0360-3016(02)02764-5
P407
P577
2002-07-01T00:00:00Z